Javascript must be enabled to continue!
Biomarkers of sarcopenia: an unmet need
View through CrossRef
Abstract
Background
Sarcopenia is a syndrome characterized by a progressive decline in muscle mass and strength, with subsequent deterioration of functional performance and increased morbidity and mortality. Its emergence may be associated with disorders that are not limited to the elderly. The multifactorial nature of sarcopenia is a major barrier to diagnosis. Several risk factors contribute to the development of sarcopenia, including age, gender, and amount of physical activity. Additionally, the pathophysiology of sarcopenia involves inflammatory conditions, endocrinal dysfunction, and metabolic alterations. Several studies have proposed numerous molecules that may be linked to the pathogenesis of sarcopenia and could be useful in the future; however, there is an unmet need to discover a sensitive, reliable, and cost-effective biomarker of muscle aging.
Main text
The objective of this research is to highlight different biomarkers of sarcopenia that reflect its multifactorial pathophysiology. A narrative review was carried out through a series of literature searches in the database MEDLINE/PubMed focusing on sarcopenia biomarkers. The following search terms were used: “sarcopenia,” “osteosarcopenia,” “muscle ageing,” “muscle failure,” “sarcopenic obesity,” “weakness,” “biomarkers,” “frailty,” “comorbidity,” “functional disability,” and “inflamm-aging.” The studies were observational and peer-reviewed. They were all carried out at a referral center, hospital, or in the community. The articles chosen all contained information about sarcopenia. Case reports and articles that did not assess people's muscle aging and sarcopenia were not considered.
Conclusion
Despite the availability of numerous functional, imaging, and biological sarcopenia markers, the inherent limitations of the assessment tools make it difficult to objectively measure the various sarcopenia domains. A valid and reliable biomarker of sarcopenia has yet to be identified. The identification of “gold standard” evaluation techniques that should be systematically used is also impacted by the variability of the populations to be assessed. In this context, the establishment of an international consensus adopting a multi-biomarker approach may be of utmost importance to tackle the different aspects of this multifactorial health-related problem.
Springer Science and Business Media LLC
Title: Biomarkers of sarcopenia: an unmet need
Description:
Abstract
Background
Sarcopenia is a syndrome characterized by a progressive decline in muscle mass and strength, with subsequent deterioration of functional performance and increased morbidity and mortality.
Its emergence may be associated with disorders that are not limited to the elderly.
The multifactorial nature of sarcopenia is a major barrier to diagnosis.
Several risk factors contribute to the development of sarcopenia, including age, gender, and amount of physical activity.
Additionally, the pathophysiology of sarcopenia involves inflammatory conditions, endocrinal dysfunction, and metabolic alterations.
Several studies have proposed numerous molecules that may be linked to the pathogenesis of sarcopenia and could be useful in the future; however, there is an unmet need to discover a sensitive, reliable, and cost-effective biomarker of muscle aging.
Main text
The objective of this research is to highlight different biomarkers of sarcopenia that reflect its multifactorial pathophysiology.
A narrative review was carried out through a series of literature searches in the database MEDLINE/PubMed focusing on sarcopenia biomarkers.
The following search terms were used: “sarcopenia,” “osteosarcopenia,” “muscle ageing,” “muscle failure,” “sarcopenic obesity,” “weakness,” “biomarkers,” “frailty,” “comorbidity,” “functional disability,” and “inflamm-aging.
” The studies were observational and peer-reviewed.
They were all carried out at a referral center, hospital, or in the community.
The articles chosen all contained information about sarcopenia.
Case reports and articles that did not assess people's muscle aging and sarcopenia were not considered.
Conclusion
Despite the availability of numerous functional, imaging, and biological sarcopenia markers, the inherent limitations of the assessment tools make it difficult to objectively measure the various sarcopenia domains.
A valid and reliable biomarker of sarcopenia has yet to be identified.
The identification of “gold standard” evaluation techniques that should be systematically used is also impacted by the variability of the populations to be assessed.
In this context, the establishment of an international consensus adopting a multi-biomarker approach may be of utmost importance to tackle the different aspects of this multifactorial health-related problem.
Related Results
#986 Sarcopenia and chronic kidney disease among adults over 45 years old: findings from CHARLS
#986 Sarcopenia and chronic kidney disease among adults over 45 years old: findings from CHARLS
Abstract
Background and Aims
Little is known about the association between sarcopenia and chronic kidney disease (CKD) among Chi...
Sarcopenia is common in ulcerative colitis and correlates with disease activity
Sarcopenia is common in ulcerative colitis and correlates with disease activity
Background/Aims: Association of sarcopenia with disease severity in ulcerative colitis (UC) is not clearly defined. We planned to estimate the prevalence of sarcopenia in patients ...
Sarcopenia as a Predictor of Mortality and Complications in Cirrhosis Patients-A Prospective Cohort Study
Sarcopenia as a Predictor of Mortality and Complications in Cirrhosis Patients-A Prospective Cohort Study
<i>Background: </i>Sarcopenia has emerged as an important prognostic factor in cirrhosis patients. A standardized definition of sarcopenia was not used ...
Prediabetes and diabetes were attributed to the prevalence and severity of sarcopenia in middle-aged and elderly adults
Prediabetes and diabetes were attributed to the prevalence and severity of sarcopenia in middle-aged and elderly adults
Abstract
Background
Sarcopenia and diabetes are both prevalent health problems worldwide. However, little is known about the relationship between pr...
Associations of body mass index and sarcopenia with screen-detected mild cognitive impairment in older adults in Colombia
Associations of body mass index and sarcopenia with screen-detected mild cognitive impairment in older adults in Colombia
Background and objectiveMore research is required to understand associations of body mass index (BMI) and sarcopenia with cognition, especially in Latin America. The objective of t...
165 Improving sarcopenia with a physiotherapy-dietetics sarcopenia management pathway in a post-acute rehabilitation unit
165 Improving sarcopenia with a physiotherapy-dietetics sarcopenia management pathway in a post-acute rehabilitation unit
Abstract
Background
Sarcopenia is a progressive and generalised skeletal muscle disorder. The prevalence of sarcopenia in Irish ...
The Frequency Of Sarcopenia In The Post-Covid Period And Its Relationship With The Clinical Course Of The Covid-19
The Frequency Of Sarcopenia In The Post-Covid Period And Its Relationship With The Clinical Course Of The Covid-19
Objectives:We planned this study and aimed to investigate the frequency of sarcopenia and the relationship between sarcopenia findings and Covid-19 disease severity in patients wit...
Clinical Relations of Sarcopenia
Clinical Relations of Sarcopenia
Sarcopenia is one of geriatric syndromes, characterized by decreased muscle mass accompanied by decreased muscle strength and/or performance. It is more prevalent with increase in ...

